The Conversation (0)
Pharma Firms Accused of Falsifying Alzheimer's Study Data
Jan. 13, 2014 02:52PM PST
Life Science Investing NewsBusiness Insider Australia reported that Japan’s health ministry is probing claims that falsified data was used in an Alzheimer’s disease study involving major pharmaceutical firms, a day after filing an unrelated criminal complaint against Swiss drugs giant Novartis (NYSE:NVS).
Business Insider Australia reported that Japan’s health ministry is probing claims that falsified data was used in an Alzheimer’s disease study involving major pharmaceutical firms, a day after filing an unrelated criminal complaint against Swiss drugs giant Novartis (NYSE:NVS).
As quoted in the market news:
Health officials said they were questioning researchers after being told false data was used in clinical testing for the $US28 million government-backed Alzheimer’s study, aimed at improving diagnosis of the disease.
The research involved 11 drugs firms, including Pfizer and Bristol-Myers Squibb and Japanese giants Takeda Pharmaceutical and Astellas Pharma, medical imaging companies and nearly 40 hospitals and medical organisations. The public and privately-financed study, dubbed J-ADNI, began in 2007.
Read the full post on Business Insider Australia